San Francisco startup Framework Therapeutics can be focusing on an oral, the moment-day-to-day GLP-1 drug called GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June when a mid-phase research showed common weight loss of all around 6% and it ideas to start A further mid-stage demo to the tip of this yr—that founder and CEO Raymond